Last reviewed · How we verify

NCT00605774

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q5

Withdrawn NA Last updated 11 December 2014
What this trial tests

NA trial testing epinephrine in Type 1 Diabetes. Withdrawn.

Quick facts

Lead sponsorVanderbilt University
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone

Drugs / interventions tested

Conditions studied

Sponsor

Vanderbilt University

Who can join

Adults 18 to 45, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

When a patient with Type 1 diabetes exercises, he or she is more prone to low blood sugar, or hypoglycemia. It is known that antecedent exercise can blunt defense responses, called counterregulatory responses to subsequent hypoglycemia in Type 1 DM, causing him or her to be vulnerable to another bout of hypoglycemia. Epinephrine is one of the important hormones in the defense of blood glucose during both exercise and hypoglycemia. We will test the hypothesis that antecedent exercise will blunt the metabolic, neuroendocrine and cardiovascular effects of subsequent epinephrine infusion in Type 1 DM.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of epinephrine

Trials testing the same drug.

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

Other Vanderbilt University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00605774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing